Clinical trials: Rectal Cancer Patients
- Condition Rectal Cancer Patients
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Breast Cancer, Colorectal Cancer
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are eligible for inclusion in this trial.
- Conditions
- Breast Cancer, Colorectal Cancer, Metastases
- Trial name
- NCT00096967
- Testing
- Avastin (bevacizumab)
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
A Screening Study Targeting Tumor-specific Antigens
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of…
- Trial name
- NCT05158621
- Testing
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gritstone bio, Inc.
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Cachexia
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.
- Trial name
- NCT00467844
- Testing
- GTx-024
- Where
- 52 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- GTx
Colorectal Cancer (CRC), Pancreatic Cancer
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency.
- Conditions
- Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06751524
- Testing
- Botensilimab, Balstililmab
- Sponsor
- Agenus Inc.
Colorectal Cancer Metastatic, Colorectal Cancer Stage III
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
This is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV
- Trial name
- COLONYVAQ™-CRC (NCT07328087)
- Testing
- Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Colorectal Neoplasm
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
This is an observational, non-interventional, uncontrolled, multicentric safety study in subjects with epidermal growth factor receptor (EGFR)-expressing, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type…
- Trial name
- NCT01074333
- Testing
- Cetuximab
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colo-rectal Cancer
Therascreen® KRAS RGQ PCR Kit
An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from patients with Colorectal Cancer (CRC) who have previously tested positive for the KRAS G12C mutation for…
- Trial name
- NCT05347745
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Colorectal Neoplasms
Stivarga Real Life Evidence in Hungary
The study aims to evaluate use of regorafenib in clinical practice in Hungary. The study should provide information about clinical characteristics of Hungarian regorafenib patients as well as information about safety and efficacy…
- Trial name
- NCT02656524
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Hungary
- Volunteers
- 400 people
- Sponsor
- Bayer
Colorectal Neoplasms
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
This is an open-label, non-randomized, prospective, multicentric, Phase IV study evaluating FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type metastatic CRC.
- Trial name
- NCT01134666
- Testing
- Cetuximab
- Where
- 40 sites in India
- Volunteers
- 165 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline